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1. Introduction
The association between prostate cancer and inflammation was first formally addressed in
the nineteen century and since then many authors have confirmed the biological and clinical
evidence of this association. However, the molecular mechanism involved is yet to be deci‐
phered.
There are two well established pathways linking inflammation and cancer: the extrinsic
pathway from conditions that cause non-resolving smouldering inflammatory responses
and the intrinsic pathway where the misregulation of oncogenes and tumor suppressor
genes switch on the expression of inflammation-related programs.
Prostate cancer is a complex and progressive disease. Over time the cells become resistance
to hormonal therapies that are designed to block the release and/or the uptake of androgens.
During this stage androgen receptor (AR) mutants are able to bind promiscuous steroids,
and may convert AR antagonists to agonists. Other hormones and their receptors are in‐
volved in the abnormal growth of the gland. Particularly, oestrogens and oestrogen recep‐
tors defined a subclass of prostate cancer with a very aggressive clinical phenotype (such as
the TMPRSS2-ERG fusion). In addition, other signaling cascades are switched on bypassing
the androgen/AR axis and favoring tumor progression. Among them, cyclooxygenase-2
(COX-2), neuroendocrine differentiation and the loss of the tumor suppressor phosphatase
and tensin homolog (PTEN), with the concomitant inhibition of the PI3K/Akt, resulting in
Bcl-2 overexpression and the burst of pro-inflammatory cytokines, chemokines and other
growth factors production, contributing all to the progression to the hormonal-resistance
disease. As in other malignancies in prostate cancer, reactive oxygen species (ROS) cause ox‐
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idative damage to macromolecules in epithelial cells and can react with other cellular com‐
ponents initiating a free radical chain reaction, thus sustaining the prostate carcinogenic
process and its progression.
The molecular mechanisms that prime the pathogenesis of cancer-related inflammation are
complex and involve a delicate interplay between tumor and its microenvironment. In pros‐
tate tumors, the switch to an angiogenic phenotype is known to be critical for its progres‐
sion. Unless a tumor can stimulate the formation of new blood vessels, it remains restricted
to a microscopic size. Inflammation and hypoxia are widely accepted as key elements in the
induction of angiogenesis.
Dissection of the diversity of cancer-related inflammation is critical for the design of innova‐
tive diagnostic and therapeutic strategies in prostate cancer.
Specifically, the following topics and molecular events are reviewed and discussed in this
chapter:
• The cytokine and chemokine orchestration and the associated downstream genetic events
that cause neoplastic transformation in the prostatic tissue.
• Acknowledging the oxidative stress imbalance in the tumoral niche as key mediators of
signaling cascades.
• The relevance of microRNAs as oncogenes and tumor suppressor genes and how micro‐
RNA expression profiles can be used for markers of prostate cancer prevention and thera‐
peutics.
• The potential of prostate tumoral cells in the inflammatory microenvironment to express
an endothelial-like phenotype and mimic vasculogenic networks.
2. Body
2.1. The cytokine & chemokine orchestration in prostate cancer: Strategies, avenues and
traits
Cytokines are a family of cell-signaling protein molecules that are secreted by various cell
types and are a category of signaling molecules used extensively in intercellular communi‐
cation. Cytokines can be classified as proteins, peptides, or glycoproteins. A variety of cyto‐
kines are secreted by cells in the tumor microenvironment and can impact on prostate
cancer growth. These cytokines can then act in a paracrine fashion on tumor cells to stimu‐
late a variety of physiological activities including cell proliferation, invasion, migration, che‐
moresistance, etc.
The tumor inflammatory microenvironment is characterized by immune cell infiltration: tu‐
mor-associated macrophages, mast cells, dendritic cells, natural killer cells, neutrophils, eo‐
sinophils and lymphocytes. These cells produce a variety of cytotoxic mediators such as
ROS and reactive nitrogen species (RNS), serine and cysteine proteases, matrix metallopro‐
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teinase (MMP), tumor necrosis factor α (TNFα), interleukins, interferons and enzymes, as
COX-2, lipooxygenase-5 and phospholipase A2, which activate or are activated by transcrip‐
tion factors such as nuclear factor κB (NF-κB) and signal transducers and activators of tran‐
scription-3 (STAT3), activator protein 1 and hypoxia-inducible factor 1α (HIF-1α) that
mediate tumor cell proliferation, transformation, metastasis, survival, invasion, angiogene‐
sis, chemoresistance and radioresistance.
Present discoveries highlight chemokines and their receptors as relevant factors for inflam‐
mation. The directed migration of a cell toward the source of a secreted protein signal,
known as chemotaxis, has been commonly associated to the leukocyte trafficking triggered
by infection and to secondary lymphoid organs. Although extensively studied as part of the
immune system, chemokines have lately been investigated as mediators of tumor develop‐
ment. Chemokines, the executors of chemotactic signals, are constitutively expressed in des‐
tined cell types and tissues maintaining the homeostasis of the hematopoietic and the
immune system. However, inflammatory chemokines, either produced by the tumor cells or
by tumor-associated cells, behave differently and their expression is induced upon inflam‐
matory stimuli promoting proliferation and angiogenesis, contributing to the malignant pro‐
gression. They certainly modify the sensitivity of prostate cancer cells to environmental
stresses such as hypoxia, oxidative stress, DNA damage, altering several pathways crosstalk
and producing hormone-refractory aggressive tumors. In addition to the classical roles de‐
scribed above, their pleiotropic effects include: potentiating the production of growth fac‐
tors, inducing growth signals, attenuating apoptosis, further linking the cytokine signaling
to the hypothesis that inflammation and inflammatory mediators rise as the seventh hall‐
mark of cancer [1]. In this section we will focus on some of the several cytokines implicated
in the prostate cancer microenvironment given that there are too many factors to describe.
2.1.1. The chemokine family acquaintance
To date, over 50 chemokines and 20 chemokine receptors have been recollected. These are
grouped into four categories, C, CC, CXC and CX3C, according to the location of the main
cysteine residues near the N-terminal domain of these proteins [2]. Chemokine binding to
their corresponding seven transmembrane-domain G-protein-coupled receptors causes the
activation of signal transduction networks leading to chemotaxis. These receptors have been
implicated in the migration of breast, prostate and lung cells to secondary sites in the bone
[3]. Up to date the most relevant chemokine receptors in prostate cancer dissemination, are
CXCR4, CXCR7 and CXCR6 [3].
The CXCR4/CXCL12 axis exerts multifactorial effects and has been related to both, the hom‐
ing of tumor cells to specific organs and the growth of tumor cells at specific locations.
CXCL12, also known as SDF-1 (stromal derived factor 1), is considered a homeostatic che‐
mokine which regulates the hematopoietic cell trafficking and secondary lymphoid tissue
architecture. It is constitutively expressed in several organs including lung, liver, skeletal
muscle, brain, kidney, heart, skin, bone marrow and its secretion is linked to tissue damage.
CXCR4 is expressed in endothelial cells and pericytes of hypoxic, injured, or pathological
tissues. Of note, endothelial precursor cells also express and secrete CXCL12. In turn,
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CXCR4 is widely expressed on hematopoietic cells including CD34+ hematopoietic stem
cells, T- and B-lymphocytes, monocytes and macrophages, neutrophils and eosinophils as
well as by brain, lung, colon, heart, kidney, liver endothelial and epithelial cells, microglia,
astrocytes, neuronal cells, and progenitor cells including endothelial and smooth muscle
progenitors. Functional CXCR4 is expressed on embryonic pluripotent stem cells and sever‐
al types of tissue-committed stem cells. These cells with functional CXCR4 expression mi‐
grate and/or invade along CXCL12 gradients. CXCR4+ pro-angiogenic cells include
immature and mature hematopoietic cells, endothelial precursor cells, and smooth muscle
cell progenitors, which have direct or indirect pro-angiogenic properties. Interestingly,
CXCL12 plays a role in the mobilization and recruitment of these cells to the neo-angiogenic
niches supporting revascularization of ischemic tissue and tumor growth [4]. This axis has
been strongly implicated in prostate cancer tumorigenesis and progression [5].
2.1.2. Chemokines and their relevance in the metastatic behavior of prostate cancer
Metastases is a multistep process including: invasion of the primary tumor cells to adjacent
tissue, intravasation, dissemination through the blood or lymph, extravasation and seeding,
adapting to a different tissue microenvironment and finally proliferating in such distant or‐
gans. This process involves both the selection of features that favor cancer cells growth and
the concomitant alteration of the stroma generating a “fertile soil” which facilitates invasion,
anchoring and survival of metastatic cells [6].
Prostate neoplasms have a striking tendency to metastasize to bone. The molecular mecha‐
nisms underlying the bone homing behavior have yet to be decoded. However, such mecha‐
nisms may include signaling cascades that induce a vascular pathway, that produce the
trigger of chemotactic factors by bone marrow stromal cells and the production of growth
factors within the bone, reinforcing the survival and proliferation of tumoral cells. It is of
common knowledge that hematopietic stem cells are directed to the bone during bone mar‐
row transplantation and human fetal development [7, 8] and CXCL12/CXCR4 appears in
this scene as key molecules in bone seeding. Metastatic prostate cancer cells may use a simi‐
lar pathway to localize to the bone. Several human prostate cancer cell lines express func‐
tional CXCR4 and differential levels of its ligand alter physiological processes of these cells
such as adhesion, migration and invasion, assigning a role for this axis in prostate advanced
disease. It is worth mentioning some controversial reports regarding the expression of this
receptor and its ligand in prostate cancer. Mochizuki et al. [9] reported that the expression of
CXCR4, but not its ligand, was increased in prostate carcinoma indicating that prostate can‐
cer cells may also be affected by exogenous SDF-1. However, other authors showed high ex‐
pression of both, ligand and receptor [10].
Interestingly, the blockade of CXCR4 inhibited the expression of vascular endothelial
growth factor (VEGF) and the concomitant angiogenesis and even reduced significantly
bone metastasis in vivo [11]. Furthermore, CXCR4 is positively regulated by AR [12]. Andro‐
gen-induced CXCR4 expression was functional in TMPRSS2-ERG-positive prostate cancer
cells, further indicating the relevance of this chemokine in prostate cancer metastasis [13].
The immunohistochemical pattern of CXCR4 expression in patients with metastatic prostate
Advances in Prostate Cancer426
cancer has shown that high expression of this chemokine in tumors had poorer cancer-spe‐
cific survival than patients with low expression of CXCR4. This receptor expression has
proved to be a useful prognostic factor for patients with metastatic prostate cancer treated
with androgen-withdrawal therapy [14].
Strikingly, regulation of CXCL12 expression in the tumor microenvironment has been poor‐
ly studied. Some reports indicate that hypoxia may induce its expression in endothelial cells
and in prostate tumor cells [5]. Could CXCL12 have an additional role to its chemo-attrac‐
tant properties? Could it also act as a growth factor or prevent the apoptosis of tumoral cells
enabling metastasis to take place? These questions still need to be answered.
CXCR7 (RDC1), a second receptor for CXCL12, regulates a spectrum of normal and patho‐
logical processes but fails to couple to G-proteins and to induce the typical chemokine recep‐
tor mediated cellular responses. It also binds to CXCL11 and dimerizes with CXCR4. This
receptor with dual specificity is up-regulated in many tumors, but its function within the tu‐
moral niche needs further clarification [15]. Studies show that CXCR7 expression provides
proliferation and survival advantages and increased adhesion properties between prostate
cancer cells and the host endothelial cells. It is also more highly expressed in prostate meta‐
stases (specially those to the bone) compared to primary tumors and elevated levels of
CXCR7 correlate with the aggressiveness of the disease. In the vasculature, the expression of
CXCR7 is elevated in endothelial cells associated with tumors [16] and this chemokine re‐
ceptor has been further linked to tumor angiogenesis in vivo [17].
Other inflammatory mediators may regulate CXCR7 function. Of note, high serum levels of
IL8 have been reported in patients with advanced metastatic prostate cancer. In primary
prostate carcinoma tissues, IL8 strongly correlates with biochemical prostate specific antigen
(PSA) recurrence and CXCR7 expression is induced by IL8 in prostate tumor cells. As sur‐
vival following androgen deprivation is a critical step in the emergence of castration-resist‐
ant tumors, IL8–induced up-regulation of CXCR7 may enhance the survival and
proliferation properties of those tumor cells. Thus the up-regulation of CXCR7 induced by
IL8 emerges as a promoter of castration-resistant tumors survival [15]. Moreover, CXCR7-
depleted tumors showed significantly reduced levels of relevant factors for prostate tumori‐
genesis like cyclin D1, VEGF and phosphorylated epidermal growth factor receptor [15].
There is also additional evidence for a potential role of CXCR7 as a CXCL12 scavenger, sug‐
gesting that this receptor in turn modulates the activity of CXCR4 in tumor formation and is
critical for the fine-tuning of the motility of hematopoietic cells in the bone marrow and
lymphoid organs.
However, the blockade of the CXCR4 and CXCR7 only partially impaired the metastatic be‐
havior of prostate cancer in vivo, arguing that other functional chemokine/chemokine recep‐
tor pairs may be envolved in prostate cancer progression [18].
The third chemokine receptor noteworthy in prostate cancer is CXCR6, displaying high ex‐
pression not only in prostate cancer cell lines but also in prostate tissues [19]. This receptor
is also known as Bonzo, STRL33 or TYMSTR. In humans, Bonzo is expressed by small sub‐
sets of T cells and CD16+ cells, but not by B cells, monocytes or dendritic cells [20].
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CXCL16 is one of the two known transmembrane chemokines. It is also constitutively ex‐
pressed on fibroblasts, keratinocytes and cancer cells of various origin tissues [19]. CXCL16
was identified as the ligand for this receptor and was found to signal through NF-κB via
heterotrimeric G proteins/PI3K/PDK-1/Akt/IKK/IκB [21]. It was also reported to signal
through the Akt/mTOR pathway [22]. A variety of chemokines contain a conserved se‐
quence motif (ELR, glutamic acid-leucine-arginine) that precedes the first cysteine residue
near the amino-terminal end which is critical for the receptor binding, for the chemotactic
activity and for the promotion of angiogenesis. Intriguingly, although lacking an ELR motif
in the chemokine domain, CXCL16 appears as proangiogenic. CXCR6 was shown to regu‐
late blood vessel formation by an autocrine/paracrine loop established between prostate
cancer and endothelial cells and was observed that both IL8 and IL6 levels were altered in
response to changes in CXCR6 expression [18]. The striking similarities between CXCL16
and CXCL12 are likely to result in additive effects [23]. Moreover, CXCL12 and CXCL16
were observed in tissues enriched with plasma cells and in cultured human bone marrow
stromal cells [23]. Thus, plasma cells are likely to be recruited to bone marrow and other tar‐
get tissues via CXCR4 and CXCR6 [18]. CXCL16 not only attracts T cells and natural killer T
cells toward dendritic cells but also supports their firm adhesion to dendritic cells [24]. Tak‐
en together, high CXCL16/CXCR6 expression may be strongly related to aggressive cancer
behavior, and particularly, high-secreted ligand expression to bone metastases of prostate
cancer [19].
While it is well accepted that chemokines promote tumor development, these molecules
may in turn be used to the benefit of cancer patients, acting in the recruitment of dendritic
cells and /or effector cells or for their angiostatic properties. However, chemokine-mediated
recruitment of immature dendritic cells within tumors, due to factors produced by the tu‐
mor milieu, may induce immune tolerance. In this context, the balance between positive and
negative effects should be examined when designing novel strategies to eradicate tumors
based on chemokine targeting.
2.1.3. Role of IL8 and IL6 in the transition to hormone refractory prostate cancer
Prostate cancer cells and the surrounding stroma are exposed to a plethora of interleukins
and chemokines, receiving their signaling stimuli, re-enforcing tumor-promoting functions.
Similar to other chemokines that recognize and bind G-protein-coupled receptors, IL8 acts
through CXC receptors. The expression of CXCL8 (also known as IL8), one of the best-char‐
acterized members of the chemokine family, has been described as a key effector in prostate
cancer. Normal prostate epithelial cells and tissues produce low amount of IL8, whereas
prostate cancer cells from primary and metastatic tumors produce progressively greater
amounts [25]. High levels of CXCL8 also correlate to an elevated adherence of the prostate
tumor cells to the endothelium, hence increasing angiogenesis, tumorigenicity and lymph
node metastasis in vivo [26, 27]. Even more, CXCL8 is a transcriptional target of NF-κB and
its expression is elevated in androgen independent prostate cancer, contributing to the tran‐
sition to a castration-resistant state and to resistance to standard chemotherapeutic drugs
[28]. To date, the chemotherapy strategy utilized for advanced prostate cancer disease is
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based on the combination of docetaxel (a cytostatic drug) with prednisone (a glucocorticoid
prodrug). However, this therapeutic strategy shows a modest survival benefit over pallia‐
tive care, where many patients respond initially, but eventually develop a resistance to do‐
cetaxel. Among other factors, increased IL8 production decreases the sensitivity of hormone-
resistant cells to the cytotoxic chemotherapeutic agents and also reduces prostate cancer cell
apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In
experimental prostate cancer a naphthalimide was shown to decrease IL8 expression and to
enhance taxol activity when co-administered with this compound. Thus, negative regulators
of this chemokine could emerge as second line treatment for patients with docetaxel-resist‐
ant advanced prostate cancer [29].
One of the most interesting mediators clearly implicated in prostate cancer is IL6, a multi‐
functional cytokine, produced by inflammatory cells, osteoblasts and even prostate cancer
cells. There are multiple lines of clinical and experimental evidence preponderantly showing
that IL6 contributes to prostate cancer progression. Both, patients with prostate cancer and
patients with advanced metastatic disease display high expression levels of IL6 and its solu‐
ble receptor in the circulating plasma [30]. These observations have led to study whether
this axis could predict biochemical recurrence in radical prostatectomy patients [31] provid‐
ing a rationale for the clinical relevance of IL6 as a prognostic factor. In particular, a phase II
study assessed the efficacy of siltuximab, in men with castrate resistant prostate cancer that
had been treated with one prior chemotherapy with the primary endpoint being PSA re‐
sponse rate (defined by a 50% reduction of PSA) [32]. This drug, also known as CNTO 328,
is a human-mouse chimeric monoclonal neutralizing IL6 antibody. The response rate was
small and no men with disease had a Response Evaluation Criteria in Solid Tumors (RE‐
CIST) response. This criterion defines a set of rules that assesses whether a patient improves
("responds"), stays the same ("stabilizes"), or worsens ("progression") during treatments. The
results obtained evidenced the lack of a beneficial therapeutic effect of IL6 neutralization in
patients with advanced androgen resistant disease. However, there are still some positive
prospects for IL6 neutralization, providing an additional benefit to other chemotherapy re‐
gimes, especially in light of its anti-apoptotic effects [33].
In addition to the clinical observations, in vitro studies have provided evidence that IL6
modulates prostate cancer cell growth of hormone-refractory cells, but had no effect on the
growth of hormone-dependent cell lines [33].
IL6 has also been implicated in other aspects of prostate cancer pathophysiology such as tu‐
morigenesis in the prostate microenvironment. IL6 foremost effect is the activation of Janus
kinase (JAK) signaling and of signal transducers and activators of transcription (STAT) pro‐
teins, especially STAT3. Through this signaling pathway, IL6 stimulates autocrine activation
of insulin-like type I growth factor receptor (IGF-IR) to confer tumorigenesis [34]. Depend‐
ing on the cellular context, IL6 can also signal through MAPK and phosphatidylinositol-3
kinase (PI3K) pathways [35, 36].
This cytokine can be produced autocrinaly in castrate resistant prostate cells and can trans‐
activate the AR in those cells. However, the AR status as well as other interacting signaling
cascades will define the role of IL6 on ligand-independent AR activation, tumor formation,
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and subsequent growth. Additionally, IL6 has been proposed to initiate an intracrine signal‐
ing pathway, alternative to the androgen receptor axis, affecting metabolic enzyme levels.
Surprisingly, testosterone plasma levels were significantly increased when IL6 overexpress‐
ing prostate cancer cells were inoculated in castrated mice, showing that this cytokine regu‐
lates the expression of esteroidogenic genes in tumoral cells [5].
Overall, IL6 strongly correlates with more advanced stages of the disease, therapy resist‐
ance, poor prognosis and can be predictive of recurrence after treatment of localized cancer.
Based on all the clinical and preclinical evidence, further exploration for IL6 inhibition is jus‐
tified; however, its efficacy may greatly depend on the stage of disease or other individual‐
ized factors.
2.1.4. Tumor Necorsis factor: Linking inflammation to prostate cancer
TNF was named for its ability to induce rapid haemorrhagic necrosis of experimental can‐
cers [37]. However, it soon became noticeable that this cytokine presented anti-tumoral ac‐
tivity and cytotoxicity against several tumoral cells [38]. Currently, TNF is considered as a
relevant player in host defense and inflammation with several activities extending far be‐
yond its original anti-tumoral action. Among its effects, TNF signaling may lead to both, cell
apoptosis and necrosis, and also to tumor progression and metastasis by switching on sur‐
vival genes [39].
TNF signals through TNF receptor 1 (TNF-R1) and TNF-R2. While TNF-R1 is expressed con‐
stitutively in most tissues, TNF-R2 is modulated and is mostly found on immune system
cells. TNF binds to the death domain containing TNF-R1 to recruit TNF receptor-associated
death domain (TRADD), Fas-associated death domain (FADD) and caspase-8, forming the
death-inducing signaling complex [40]. Interestingly, when TNF-R1 is activated, it also re‐
cruits receptor-interacting protein (RIP) and TNF receptor-associated factor 2 (TRAF2) and
activates NF-κB, involved in cell survival, proliferation, anti-apoptotic activity and highly
implicated in the inflammatory response [41].
TNFα plays critical roles in cancer pathophysiology building an elaborate association be‐
tween inflammation and cancer. It functions as a key regulator of the tumor microenviron‐
ment, promoting tumor progression, even in the absence of invading inflammatory cells
[42]. It facilitates cancer development acting directly on neoplastic cells or indirectly through
endothelial and other inflammatory cells [43]. However, the mechanisms by which TNFα
enables these events are not fully described. A recent publication from Davis et al. [44] ex‐
plains the dichotomy of TNFα effect on the control of apoptosis in prostate cancer cells.
These authors propose a physiologic role for TNFα in prostate regression after androgen
withdrawal. This factor is required for castration-induced prostate regression, but mem‐
brane-bound TNFα protein and stromal cell specific TNFα mRNA levels increase in rat
prostate after castration, which is coincident with a paracrine effect of TNFα in prostate can‐
cer regression. However, when wild-type non-castrated mice were treated with TNFα no re‐
gression of the gland was observed [44]. All these evidences showed that this cytokine acts
in the context of supplemental castration-induced signals.
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Summarizing, the chemokine scene displays a vast crosstalk of pathways involved in the
day-to-day dialogue between the cancer cells and the inflammatory microenvironment. The
challenge relies in identifying the homeostatic target/targets that govern this setting in order
to successfully re-direct the therapeutic efforts against prostate cancer.
2.2. The oxidative stress imbalance in the prostate tumor: Gearing the journey to cancer
The development of cancer is a complex process. Cancer cells associate, both in primary
as well as in secondary colonization sites with resident stromal fibroblasts, smooth muscle
cells,  macrophages,  endothelium,  neurons  and  migrating  cells  at  metastatic  niches  and
phenotypically  and  genotypically  activate  them,  triggering  different  signaling  mecha‐
nisms. During this process, the cancer cells and cells in the cancer microenvironment “co-
evolve” in part due to oxidative stress, and acquire the ability to mimic other cell  types
(which can be termed osteomimicry, vasculomimicry, neuromimicry and stem cell mimi‐
cry),  and undergo transition from epithelium to mesenchyme with definitive behavioral
modifications. Prostate cancer cells co-evolve in their genotypic and phenotypic characters
with stroma and acquire  osteomimetic  properties  allowing these cells  to  proliferate  and
survive in the skeleton as bone metastasis [45]. ROS, RNS and other factors implicated in
oxidative  and  nitrosative  stress  alters  the  homeostatic  milieu,  affecting  macromolecules
and damaging cell membranes, altering organelles permeability and function. Thus co-tar‐
geting different players in this complex scenario will be an effective treatment alternative
for prostate cancer progression.
2.2.1. The prostate and its oxidative defense barriers
The normal prostate epithelium consists of prostatic ducts that contain basal cells, stem cells,
secretory luminal cells and neuroendocrine cells. The stromal component consists of smooth
muscle, fibroblasts, vascular endothelial cells, nerve cells, inflammatory cells, insoluble ma‐
trix and soluble factors. Inflammation is clearly associated to the early stages of prostate car‐
cinogenesis [46]. The macrophages in the tumor microenvironment produce ROS and RNS.
The increase in reactive radicals such as superoxide (O2•−), hydrogen peroxide (H2O2), hy‐
droxyl radical (HO•), etc. produces DNA damage, causes genetic mutations and initiates/
promotes cancer progression. Some molecules implicated in prostate atrophy include p53
and AR mutations, hypermethylation of the CpG island of the promoter of gluthathione S
tranferase-P1 (GSTP1), decreased activity of manganese superoxide dismutase (MnSOD)
and increased expression of NADPH oxidase 1, which initiate high grade prostatic intraepi‐
thelial neoplasia (PIN) and progressive prostate cancer [45].
The prostate gland depends on the androgen/AR signaling for growth. Activation of this ax‐
is in advanced prostate cancer has been attributed to various mechanisms, including AR hy‐
persensitivity, de novo intraprostatic androgen synthesis, promiscuous AR activation via
adrenal androgens, non-androgenic steroids and non-canonical AR activation via growth
factors and cytokines through intracellular signal-transduction pathways [47]. These mecha‐
nisms may result from abnormalities in the AR status (e.g., mutation, splice variants) and/or
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in the levels of its co-regulators. Furthermore, some AR splice variants have been identified
with constitutive effects in the absence of ligands [48].
ROS are endogenously generated during cellular metabolic processes. It can also come from
external sources. Thus, excessive ROS production or impairment of antioxidant defense sys‐
tems can induce oxidative stress. This increase in ROS levels may contribute to the initiation
and development of various cancers, including prostate cancer, because oxidative stress reg‐
ulates cellular fate in various systems. ROS are considered to be tumor initiators/promoters
given the potential for induction of DNA damage. Furthermore, signaling pathways in re‐
sponse to intracellular changes in ROS levels may trigger proliferation, apoptosis and senes‐
cence, events highly implicated in all the stages of the carcinogenic process. However, little
is known about the exact molecular machinery that mediates ROS function in the tumori‐
genic process. Several transcription factors that regulate AR activity/transcription are impli‐
cated in oxidative stress, among them, NF-κB, c-Myc, CREB, Sp1 and Foxo3a [49].
Interestingly, castration-induced oxidative stress in prostate cancer cell lines increased AR
levels through the overexpression of an oncogene member of the basic helix-loop-helix tran‐
scription factor Twist 1, which regulates the expression of AR by binding to E-boxes in its
promoter, resulting in a gain of castration resistant phenotype [50] and being responsible of
metastasis [51]. Evidently, there is a connection between oxidative stress and androgen dep‐
rivation in prostate cancer, which is also supported by previous observations of increased
oxidative damage associated to the development of malignancies [52]. Of interest, when
comparing the expression profile of castration resistant prostate cancer gene with the genetic
landscape of hormonal sensitive tumors, the endogenous antioxidant defense system is
clearly repressed, in particular MnSOD, which regulates ROS production by converting su‐
peroxide to a less reactive species, acting as a ROS scavenger. Hence, MnSOD in advanced
prostate cancer could be mechanistically linked to AR reactivation. An array for transcrip‐
tion factor DNA binding activity showed that AR (among other transcription factors) binds
to DNA after MnSOD knocked-down [53]. These findings correlate with a clear transcrip‐
tional repression of stress-related genes [54].
2.2.2. Is oxidative stress governing the co-regulators of nuclear receptors?
Co-regulators of transcription orchestrate the action of nuclear receptors. Each tissue has a
"quantitative finger print" of co-activators based on the relative inherited concentrations of
these molecules. When the cellular concentration of a co-activator is altered, genetic dys‐
function usually leads to a pathologic outcome. Co-regulators contain the potential to effi‐
ciently promote cellular pathologies by coordinately misdirecting multiple independent
functions such as oncogenesis. During the development and progression of prostate tumors
there are a misregulation of AR co-activators, many of them play a critical role in redox
maintenance protecting cells from cytotoxicity produced by oxidative stress. That is the case
with peroxiredoxin (Prx), a gene elevated in cancer with anti-oxidant capacity. Prx1, a co-
activator that facilitates the binding of androgen to the AR, is regulated by nuclear factor
(erythroid-derived 2)-related factor 2 (Nrf2), a transcription factor also induced by oxidative
stress. Another member of this family, Prx2, is also regulated by oxidative stress but in this
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case through Foxo3a, another transcription factor implicated in AR transcription and cellu‐
lar responses to oxidative stress and overexpressed in the castrate resistant-disease. Remark‐
ably, the subcellular distribution of co-regulators seems to be relevant in the regulation of
the AR activity. While cytoplasmic Prx2 enhances AR transactivation, its nuclear localization
decreases the receptor activity, suggesting that the redox status of the nucleus and cyto‐
plasm might affect AR signaling through this co-regulator [55].
2.2.3. Oxidative stress and tumor-stroma co-evolution
Since the initial seed and soil hypothesis elaborated by Paget in 1889 [56], the relevance of
the tumor microenvironment in the carcinogenic process is continuously on scene. Tissue re‐
combination experiments with mixed prostate stromal/epithelial cell xenografts surprisingly
revealed that transformation of epithelial cells is accompanied by a transdifferentiation of fi‐
broblasts. Prostate stroma is mainly composed of fibroblasts and smooth muscle cells, and
an intermediate cell type described as myofibroblast. The highly proliferative stromal cells
immediately surrounding malignant glands have been described as “reactive stroma” or
“carcinoma-associated fibroblast” (CAF) [57]. Wound repair exhibits a fibroblastic switch to
a myofibroblast-like phenotype, with the subsequent extracellular matrix (ECM) remodeling
through angiogenesis and increased protease activity [58]. The “reactive stroma” of a malig‐
nant tumor may parallel the granulation tissue of a healing wound in many ways, behaving
as wounds that never heal. This “reactive stroma” comprises multiple cell types, which have
been altered from their original state to become permissive of prostate cancer cell progres‐
sion. In human prostate cancers, the “reactive stroma” displays increased number of myofi‐
broblasts, amplification of ECM proteins, and increased local vascular density, properties
almost identical to those seen in granulation tissue. Intriguingly, there is still no effective
marker of “reactive stroma” available. The receptors activated by serine proteases (PARs)
are good candidates as PARs play key roles in tissue remodeling and cancer invasion. Other
key signaling mediators also involved in the “reactive stroma” phenoptype include tumor
growth factor beta (TGFβ), partly responsible for fibroblast transdifferentiation. Other fibro‐
blastic and smooth muscle markers participate in the transformation phenomena, such as vi‐
mentin and smooth muscle α-actin. However, TGFβ also affects the cancer cell itself,
accomplishing contrary roles in the different stages of cancer evolution. Even in precancer‐
ous PIN lesions elevated TGFβ expression was detected in epithelial cells. In addition to
TGFβ, chronic inflammation has also been the focus in the development of prostate cancer.
Several characteristics of chronic inflammation are increased, such as the induction of the
proinflammatory enzyme COX-2 and production of ROS and RNS. In turn, the infiltration of
macrophages and leukocytes together with COX-2 activation, further enhances the burst of
oxidative stress, promoting a more aggressive phenotype.
2.2.4. Oxidative stress triggers metabolic reprogramming
Mounting evidence recollected in the last paper of Hanahan and Weinberg [59] display com‐
pelling data on oxidative stress as a scaffold of the well-established hallmarks of cancer. Oxi‐
dative stress players are expressed abnormally in tumors, positively affecting compulsory
Inflammatory Microenvironment in Prostate Carcinogenesis
http://dx.doi.org/10.5772/52636
433
stages of the carcinogenic process, by stimulating cell proliferation and anchorage independ‐
ent cell growth, causing insensitivity to apoptosis, sustaining de novo angiogenesis, and by
altering the migration/invasion program through metabolic and epigenetic mechanisms.
ROS mediates ligand-independent transactivation of receptor tyrosine kinase and ERK acti‐
vation affecting proliferation, promoting tissue invasion and metastatic dissemination due
to MMP secretion/activation. Furthermore, ROS induce the release of VEGF and angiopoie‐
tin promoting angiogenesis and evading apoptosis/anoikis [60-62].
In cancer cells, high levels of ROS can result from increased basal metabolic activity, mito‐
chondrial  dysfunction  due  to  hypoxia  or  mitophagy,  peroxisome  activity,  uncontrolled
growth factor of cytokines signaling and oncogene activity, as well as from enhanced ac‐
tivity of known ROS sources as NADPH oxidase, COX or lipoxygenases [62]. It is well ac‐
cepted that the activity of oxidants on tumors depends on their mutagenic potential, their
capacity to rule the intracellular signaling pathways governing cellular homeostasis  and
their recognized role in stromal reactivity, mandatory for cancer development and dissem‐
ination [63, 64].
Cell vulnerability appears as a consequence of the oxidative status of their constituents pro‐
moting spontaneous and therapy induced cell death. Thus, resistance to oxidative stress is
positioned as a major mechanism of tumor chemo- and radio-defense.
The tumor hypoxic microenvironment as well induces this “reactive stroma”, affecting the
cancer cells motility, and consequently generating a more aggressive tumor, which can met‐
astasize to the bone. Hypoxia generates ROS production and likewise anti-oxidants agents
have shown to suppress hypoxia induced epithelial to mesenchymal transition (EMT), im‐
pairing the metastatic phenotype [65]. The “reactive stroma” recruitment to the cancer foci
begins early during carcinogenesis and its co-evolution is predictive of human cancer pro‐
gression, which is facilitated by tumor-stroma interactions.
It  is  of  particular significance that  many genes,  which are regulated by oxidative stress,
are targets of NF-κB [66]. NF-κB is constitutively activated in human prostate carcinoma
and  correlates  with  disease  progression  [67].  NF-κB  is  an  inducible  transcription  factor
that belongs to the Rel/NF-κB family. Increasing evidence suggests that inhibition of NF-
κB activity in prostate cancer cells can suppress angiogenesis, invasion and metastasis by
down-regulating the expression of NF-κB downstream target genes, such as VEGF, plas‐
minogen  activator  type  urokinase  and  MMP-9  [68].  Additionally,  heme-oxygenase  1
(HO-1), the rate-limiting enzyme in heme degradation, confers cytoprotection against oxi‐
dative stress and inflammation [69]. This protein exerts vital metabolic functions limiting
the axis of heme degradation and maintaining the cellular homeostasis. Several signaling
molecules are implicated in the cytoprotection conferred by HO-1,  including NF-κB and
PI3K/Akt  [70].  Although  classical  recognized  as  a  microsomal  protein,  its  presence  has
been  detected  in  other  subcellular  compartments  [71,  72].  Recent  studies  have  reported
that HO-1 suffers a proteolytic degradation in its hydrophobic C-terminal domain, which
would facilitate its entrance to the nucleus [73]. It has been proposed that HO-1 possesses
in the nucleus a non-catalytic canonical function participating in the regulation of the ac‐
tivity of several nuclear transcription factors and also regulating its own transcription [72,
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73]. Moreover, it has been documented HO-1 nuclear expression in human primary pros‐
tate  carcinomas [71].  It  has also been reported that  it  impairs  prostate  tumor growth in
vivo and down-regulates the expression of target genes associated with inflammation and
angiogenesis [74, 75]. However, clinical data demonstrated a statistically significant differ‐
ence  in  HO-1  epithelial  expression  between  benign,  high-grade  PIN,  localized  prostate
cancer,  and  advanced  prostate  cancer,  where  castration  resistant  disease  presented  the
highest HO-1 expression followed by benign tissue. This work provides experimental evi‐
dence for a cross talk between epithelial HO-1 expression and PTEN deletions, which are
associated with adverse clinical outcome [76].
Altogether these findings may indicate that the oxidative stress imbalance may strongly in‐
fluence the prostate carcinogenic process and may also cooperate in the bone homing of
prostate cancer, the most clinically significant aspect of this disease. The stromal–epithelial
interaction gains therapeutic relevance, as prostate carcinoma cells must induce the hospital‐
ity of bone cells in order to take up residence in an osseous microenvironment.
2.3. MicroRNAs as emerging key players in the etiology and progression of prostate
cancer − Clinical implications
MicroRNAs (miRNAs o miRs) are short non-coding RNAs (18-24 nucleotides) regarded as a
novel class of regulatory molecules that suppress gene expression at the post-transcriptional
level. miRNA genes are, in general, regulated and transcribed in the same manner as a pro‐
tein-coding gene. They are transcribed by the RNA polymerase II into long primary tran‐
scripts (pri-miRNAs) that can contain the precursors of one to several clustered miRNAs.
These primary transcripts are then cleaved by endonucleases (Drosha) to produce the pre-
miRNAs which consist of ~70-nucleotide hairpin structures. The pre-miRNAs are further
processed in the cytoplasm by the Dicer complex into the mature miRNAs which are incor‐
porated into the RNA-induced silencing complex (RISC) that execute the regulatory activity
through the binding to the 3’ untranslated region (3’UTR) of target mRNAs having comple‐
mentary sequences. The formation of the mRNA/miRNA duplexes, lead to mRNA degrada‐
tion, inhibition of translation, or a combination of both.
At present, there are more than 1,600 human miRNAs entries in the miRBase release 19 [77].
Each of these molecules may regulate the expression of hundreds of genes within one cell,
and one particular target may be regulated by several miRNAs via different binding sites,
creating an extremely complex regulatory network for gene expression. Indeed, it has been
estimated that about 60% of the protein-coding genes are targets of miRNAs [78]. In recent
years, rapidly growing evidence has established the significance of miRNAs in different
physiological processes such as development and differentiation, cell cycle, metabolism, he‐
mostasis and apoptosis [79].
On the contrary, an altered expression of these regulators play an important role in diseases,
including carcinogenesis [80]. Quantitative alterations, either genetic or epigenetic, may
modify the expression levels of miRNAs, and are associated with tumor development and
progression in various tumors. More than half of the deregulated miRNAs map at, or near
to, cancer-associated loci prone to deletions, amplifications and translocations [81]. Qualita‐
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tive changes can also arise when there are mutations that disrupt or create miRNA recogni‐
tion sites. Therefore, miRNAs may contribute to carcinogenesis acting as oncogenes, called
oncomirs, if they promote tumor growth when they are over-expressed. They may also act
as tumor suppressors when they stimulate cancer development and progression when they
are down-regulated. As a general rule, oncomirs target tumor-suppressor gene mRNAs (e.g.
miR-21 regulates PTEN), and tumor-suppressor miRNAs target proto-oncogene mRNAs
(e.g. let-7 regulates KRAS).
miRNAs, as well as mRNAs, display tissue-specific expression profiles and, therefore, they
may have different roles in cells from different origins. An example of this disparity is
miR-125b which can have a tumor suppressor activity in ovarian and breast cancers but act
as an oncomir in prostate cancer, thyroid cancer, neuroblastoma and glioblastoma [82]. The
study of the global miRNA expression levels (miRNAome) has been rising in the past years
and abundant miRNAome data are currently available for several cancers. The miRNA ex‐
pression patterns in different types of tissues have been reported to be more predictive of
tumor origin and differentiation status than mRNA profiles because, unlike mRNA expres‐
sion, a modest number of miRNAs (~200 in total) might be sufficient to classify human can‐
cers [83]. In prostate cancer, the expression of several miRNAs and their target mRNAs are
altered and involved in development, invasion and metastasis. Nevertheless, the data on
miRNA expression in prostatic tumors are still conflicting and, at present, a conclusive miR‐
NA profile cannot be recognized. In this section we describe miRNAs that have been stud‐
ied in the context of prostate cancer and summarize their possible application in disease
diagnosis and prognosis.
2.3.1. miRNAs associated to prostate cancer
The expression of miR-21 is up-regulated in many types of cancers, including prostate can‐
cer, glioblastoma, lymphoma, pancreatic cancer, and lung cancer, among others [84, 85].
miR-21 can act as an oncomir that contributes to prostate tumor growth, resistance to apop‐
tosis, invasiveness and metastasis. Its regulatory activity probably involves the down-regu‐
lation of the tumor-suppressor gene PTEN (commonly lost or down-regulated)
programmed cell death 4 (PDCD4), tropomyosin 1 alpha (TPM1), and myristoylated ala‐
nine-rich proteinase kinase C substrate (MARCKS), among other genes. miR-21 was found
to be over-expressed in androgen-independent prostate cancer cell lines but its expression is
low in androgen-dependent prostate cancer cells; therefore, it may be responsible, at least in
part, for the development of castrate-resistant tumors. AR can bind to miR-21 promoter re‐
sulting in an androgen-dependent transcriptional regulation of miR-21; consequently andro‐
gen-dependent miR-21 expression may contribute to prostate cancer pathogenesis. In
support of these findings, an in vivo study showed that miR-21 is over-expressed in human
prostate tumor samples compared to the matching normal tissue, and tumor growth was ac‐
celerated in xenograph models when miR-21 expression was elevated [86].
miR-221 and miR-222 are two highly homologous oncomirs that are frequently over-ex‐
pressed in different cancers. In primary prostate carcinomas and cell lines, these two miR‐
NAs inversely correlate with the expression of the tumor suppressor gene p27, which is a
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well-established marker of poor prognosis in prostate cancer and other types of tumors [87].
In vitro and in vivo experiments link these two miRNAs to prostate cancer development and
progression. Furthermore, miR-221 and miR-222 contribute to the growth and maintenance
of castration-resistant prostate cancer (CRPC) through mechanisms that comprise the AR
signaling.
Another oncomir, miR-125b, was reported to be over-expressed in androgen-independent
prostate cancer lines and was also implicated in the hormone independent growth. The
mRNA of the pro-apoptotic protein Bak1, which was found down-regulated in CRPC, is a
target of miR-125b. However, this miRNA was also suggested to act as a tumor suppressor
in a different context because it was found to be down-regulated in CRPC and in breast can‐
cer where it silences the expression of HER-2/neu [88]. Interestingly, it was also reported that
HER-2/neu is over-expressed in the progressing prostate tumors [89]. Therefore, the rele‐
vance of miR-125b in prostate cancer progression needs further investigation to assess its
role in prostate carcinogenesis.
miR-101-1 and miR-101-2 map in two locus (1p31.3 and 9p24.2, respectively) that are com‐
monly deleted in localized and metastatic prostate cancer. In addition, the loss of miR-101-1
or -2 is associated with the over-expression of EZH2, a histone methyltransferase enzyme
that is a direct target of miR-101. The up-regulation of this miRNA reduced the proliferation
and the invasive potential of the DU145 cell line. COX-2 is another target of miR-101, linking
the miRNAs portray to chronic inflammation and tumor development via the COX-2/pros‐
taglandins pathway [90]. In vitro studies have shown that there is an inverse correlation be‐
tween miR-101 and COX-2 in different prostate-derived cell lines, and the over-expression
of miR-101 reduces the proliferation rate of the COX-2-associated benign prostatic hyperpla‐
sia cell line [91]. Similarly, experimental models by inoculation of cells into BALB/c athymic
nude mice demonstrated that the miR-101 over-expressing clone showed a slower tumor
growth. Furthermore, the treatment of the tumorigenic BPH1 cell line (BPHCAFTD) with exog‐
enous miR-101 resulted in an inhibition of prostate cancer growth in vitro and in vivo [91].
Similarly, the over-expression of miR-128a reduced invasion capability of the androgen in‐
dependent prostate tumor cell line, DU145, and was found to be progressively decreased in
tissues from benign prostatic hyperplasia, to localized prostate cancer and to distant meta‐
stasis [92].
Another tumor suppressor miRNA that was reported to play a role in prostate cancer pro‐
gression to CRPC is miR-146. This miRNA is down-regulated in androgen-independent cell
lines and CRPC tissues compared to androgen-dependent cell lines and non-tumor epithe‐
lial tissues [93]. The mechanism of action of miR-146 consists of the inhibition of the expres‐
sion of ROCK1 (Rho-activated protein kinase 1), which is a member of the hyaluronan/
CD168 pathway involved in prostate cancer invasion and metastasis.
PKCε (protein kinase C epsilon) and ZEB2 (zinc finger E-box binding homeobox 2) are two
proteins involve in the migration and invasion capabilities of prostate cancer cells and their
expression is regulated, at least in part, by miR-205. This miRNA was reported to be down-
regulated in prostate cancer cell lines and carcinomas compared to the non-tumorigenic cell
line RWPE-1 and normal prostate tissues, respectively. miR-205 also induces genes involved
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in cell-cell junctions and down-regulates genes associated with prostate cancer progression
such as IL6, caveolin-1, EZH2, ERBB3, E2F1 and E2F5.
This list is just a small part of all miRNA alterations found in prostate cancer (For a more
complete list of miRNAs in prostate cancer, the reader may refer to the review written by
Coppola et al.[85] and Pang et al.[94]), but other players cannot be discarded.
2.3.2. miRNAs as biomarkers for prostate cancer diagnosis and prognosis
Based on the evidence that miRNAs may be deregulated in different pathologies in a tis‐
sue-specific  manner,  multiple  studies  have  investigated  the  potential  use  of  the  miR‐
NAome as a biomarker. As a consequence, a growing amount of evidence proposes that
the miRNAome can be used as a tool to better define pathological signatures and, in turn,
to accurately differentiate tumors according to their origin and cellular linage. In addition,
miRNAs meet other important requisites that may allow their use as biomarkers for can‐
cer  diagnosis  and  prognosis:  1)  miRNAs  are  remarkably  stable  molecules  in  different
types  of  clinical  samples,  including  formalin-fixed  paraffin-embedded  (FFPE)  tissues
which is the standard technique used for long-term conservation of biological samples, 2)
they can be analyzed by simple methods such as quantitative retro-transcriptase polymer‐
ase chain reaction (qRT-PCR), and 3) the lack of intricate transcriptional and translational
regulation compared to mRNA.
The tumoral expression of miR-1 and miR-133a correlates with tumor progression. Interest‐
ingly, the relapse-free survival of patients with prostate cancer can be predicted by the ex‐
pression of miR-1 in the tumor specimens. Patients with tumors having low miR-1
expression are more likely to have a biochemical relapse than patients with tumors having
high miR-1 expression [95].
Besides their intracellular function, miRNAs can also be released by cells and circulate in the
blood stream. Consequently, miRNAs can be isolated from serum and plasma; evenmore,
they can be isolated from other body fluids such as urine, saliva and semen. The discovery
of circulating miRNAs opened up intriguing possibilities to use the circulating miRNAome
as one additional biomarker to improve cancer diagnosis, determine tumor staging more ac‐
curately and predict prognosis. Some reports demonstrate that miRNA levels in body fluids
may change under certain pathological conditions, including prostate cancer [96]. For this
reason, within the past years, studies on miRNAs in cancer have burst onto the scene, and
evidence that miRNAs may represent new diagnostic and prognostic molecules in human
cancers is rapidly accumulating. However miRNA levels as tools for diagnosis and progno‐
sis in prostate cancer are still limited [96].
Although, serum and plasma levels of miR-141 seems to be one of the most promising mark‐
ers for prostate cancer diagnosis because they are consistently increased in men diagnosed
with this carcinoma compared to healthy individuals; the differences are statistical signifi‐
cant only when the comparisons are made between healthy persons and advanced prostate
cancer patients [96]. miR-141 is also elevated in prostatic tumor specimens, suggesting that
the raise of this molecule in the body fluids is originated by the tumor cells and increases as
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disease progresses. Serum levels of other miRNAs are also altered in specimens from men
with prostate cancer when compared to healthy individuals (e.g. miR-21, miR-200, miR-221,
miR-375, and others), but results are inconsistent among reports.
miR-141 was also studied as a predictor factor for prostate cancer classification. One study
showed increased levels of serum miR-141 and miR-375 in high-risk patients (Gleason score
≥8 or N1) compared to low-risk patients (Gleason score 7 or N0) [97]. Another study found
that serum miR-21 is increased in patients with CRPC resistant to docetaxel, opening the
possibility to use serum miRNAs as markers of therapeutic response as well [98]. Unfortu‐
nately, the specificity and sensitivity of miRNAs when used as single markers for prostate
cancer diagnosis and prognosis are similar to the specificity and sensitivity of other markers
currently used (e.g. PSA).
In summary, miRNAome from serum or plasma samples may not add much information for
prostate cancer diagnosis, outcome and response to therapy when used as a single biomark‐
er. In addition, it is unlikely to achieve the desire level of accuracy for prostate cancer diag‐
nosis or prognosis, because one miRNAs may be altered in many different diseases.
Furthermore, one mRNA can be affected by several miRNAs. Therefore, circulating miR‐
NAome should be considered an additional tool to improve the accuracy of current diagnos‐
tic molecules such as PSA, and other diagnostic tests such as the digital rectal exam,
echography and others. Similarly, the tumor miRNAome may help to improve the patholog‐
ical classification of prostate tumors. Up to date the miRNA profile cannot substitute other
clinical tools, but can efficiently supplement them.
2.3.3. Targeting miRNAs as therapeutic strategies
The discovery of miRNAs a decade ago and the subsequent study of their role in the patho‐
genesis of disease, unveiled a new scenario where miRNA modulators could be used in or‐
der to restore the homeostasis of an altered cell or tissue. Recently, a novel class of synthetic
inhibitory molecules (antagomirs) that compete with target mRNAs for the binding of miR‐
NAs, allowing mRNA translation, has been introduced as silencers of oncomirs. The antago‐
mirs uncover the way to miRNA-base therapeutic strategies. As the number of in vivo
studies that analyze the use of miRNAs as therapeutic molecules is restricted to a very small
number, further investigations are needed. In spite of all the data being generated, the
knowledge and understanding of miRNA in prostate cancer is still at the early stage. Once
the normal/pathological role of each alteration is deciphered, and the results validated in a
vast cohort of patients, the selected miRNAs might be attractive candidates for prostate can‐
cer diagnosis, patients’ management and therapeutic strategy.
2.4. The nuts and volts of prostate cancer survival, mastering the tumoral vasculature:
angiogenesis, vasculogenic mimicry or vessel co-option?
2.4.1. Angiogenesis as a hallmark of cancer
The hallmarks of cancer define distinctive and complementary capabilities that allow tu‐
mors to grow and disseminate. One of those capacities is the induction of angiogenesis. This
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process specifically refers to the sprouting of new blood vessels from pre-existing ones, in‐
volving proliferation of endothelial cells and migration towards pro-angiogenic molecules.
The expansion of the existing vasculature also relies on the accumulation of circulating en‐
dothelial progenitor cells. The latter are immature endothelial cells, typically arising in the
bone marrow, with the capacity to extravasate in response to pro-angiogenic factors and
promote new vessel formation known as vasculogenesis. This process also takes place in the
tumor microenvironment; however, it is generally associated with embryogenesis and de‐
velopment and involves the birth of new endothelial cells and their assembly into tubes in
addition to the sprouting. Following this morphogenesis, the normal vasculature results in a
quiescent action, becoming in the adult only an active process in wound healing events and
in female reproductive cycling, but only transiently.
The  tumor  and  its  microenvironment  display  a  completely  different  scenario,  allowing
pro-inflammatory  molecules  to  switch  on the  angiogenic  process  enabling  the  tumor  to
grow, persist and disseminate. The tumor-associated angiogenesis was previously consid‐
ered to be important in growing macroscopic tumors; however, the clinical evidence show
that  it  directly contributes to the microscopic premalignant  phase of  neoplastic  progres‐
sion, further securing its position as an integral hallmark of cancer. This angiogenic switch
is governed by angiogenic regulators that bind to stimulatory or inhibitory cell-surface re‐
ceptors displayed by vascular endothelial cells. The well-known inducers of angiogenesis
include  among  others:  VEGF-A,  TGFβ  and  IL8;  while  inhibitors  include:  thrombospon‐
din-1 (TSP-1) and angiostatin, among others. In tumors, these molecules support the rapid
division of tumor cells [59]. VEGF signaling occurs via three main subtypes of receptor ty‐
rosine kinases known as VEGFR1, VEGFR2 and VEGFR3. Its expression can be upregulat‐
ed both by hypoxia and by oncogene signaling [99, 100]. Additionally, VEGF ligands can
be sequestered in the ECM in latent forms that can then be activated by ECM-degrading
proteases such as MMP9. Also the fibroblast growth factor (FGF) family is capable of acti‐
vating VEGF and has been implicated in sustaining tumor angiogenesis. TSP-1 emerges as
a  counterpart  of  the  angiogenic  process,  that  when  activated  suppresses  proangiogenic
stimuli [101]. Of note, Ras  and Myc,  dominant oncogenes can also upregulate angiogenic
factors in the tumoral microenvironment, and these signals can also be produced indirect‐
ly by immune inflammatory cells.
It is of particular interest the fact that angiogenesis inhibitors, such as TSP-1, angiostatin and
endostatin offer natural barriers to tumor angiogenesis. This was described by Ribatti et al.
[102], followed by several studies reporting other endogenous inhibitory agents. Most of
these molecules appear to derive from proteolytic cleavage of structural proteins that are not
angiogenic regulators per se, and some can be detected in normal mice and human plasma.
These agents serve under normal circumstances as physiologic rheostats modulating angio‐
genesis during tissue remodeling and wound healing but may also act as intrinsic barriers to
the sustained angiogenesis in emerging neoplasias.
How do these counterpart molecules behave in the tumoral process? How can we decipher
the cross talk of this aberrant mix of proangiogenic signals? A massive amount of informa‐
tion describes the features of a cancer cell. However, it is wise to acknowledge the differen‐
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tial concepts of causes, oncogenic events, signal transduction programs, and hallmarks to
show that there is a complexity under this network of interrelations that dynamically
changes in different cells, between cells, and most importantly at different times in any giv‐
en cell. Cancer is an evolving, heterogeneous system, hence the intricacy of the forming vas‐
culature supporting tumor growth and progression.
2.4.2. Intussusception and vessel co-option
While sprouting angiogenesis requires VEGF for endothelial cells to proliferate, migrate and
maturate into new vessels, in the absence of this factor, the blood vessels split into new ves‐
sels without the need of endothelial cell proliferation. This phenomena is termed intussus‐
ception and has been demonstrated in various tumors [103]. Intussusception cannot be
stopped by anti-VEGF strategies.
Intussusceptive microvascular growth refers to vessel  network formation by insertion of
connective tissue columns,  called tissue pillars,  into the vessel  lumen and to  the  subse‐
quent growth of these pillars, resulting in the sub-division of the vessel lumen. Intussus‐
ception is  observed in  a  variety  of  normal  and malignant  tissues.  It  is  faster  and more
inexpensive than sprouting,  occurring within hours or even minutes and besides its  au‐
tonomy from endothelial  cell  proliferation,  it  also  becomes  independent  from basement
membrane degradation, or even invasion of the connective tissue. However, intussuscep‐
tive microvascular growth displays a limiting factor: it  can only work on existing vessel
networks. Therefore intussusceptive microvascular growth has the ability to increase the
complexity  and  density  of  the  tumor  microvessel  mesh  already  built  by  sprouting.  Al‐
though the molecular networks underlying this vascularization mechanism are poorly un‐
derstood, the role of some local stimuli, such as intravascular shear stress, may induce a
cascade of physiological or pathological reactions in endothelial cells, such as new capilla‐
ry development by tissue pillar formation [104].
The absence of intense endothelial cell proliferation in intussusceptive microvascular
growth implies that neovascularization by this mechanism would be resistant to angiosup‐
pressive treatment in itself. Clinically, accumulation of tumor blood vessels by intussuscep‐
tive vessel growth is associated with a poor outcome for various types of cancers [105].
Until recently, vascularization of malignant tumors was considered the exclusive result of
directed capillary ingrowth (endothelial sprouting). However, recent advances have been
made in identifying the processes involved in angiogenesis and vascular remodeling. Con‐
sequently, the simplistic model of an invading capillary sprout has been deemed insufficient
to describe the entire spectrum of morphogenic and molecular events required to form a ne‐
ovascular network. Cancer tissue can acquire its vasculature by co-option of pre-existing
vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid an‐
giogenesis, or vasculogenic mimicry [103, 105].
Before discussing the different ways a tumor is vascularized, we should highlight that these
mechanisms may not be mutually exclusive; the literature has shown that in most cases
there is a cross-talk between these systems, participating in conjunction in physiological as
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well as in pathological angiogenesis. Although the various types of cancer vascularization
may share similar molecular signaling cascades and may be controlled partly by almost
identical regulatory factors, a significant variety of differences also prevail.
It is widely accepted that the primary tumors and metastases have an initial avascular
growth stage and then the angiogenic switch is turned on to support the exponential tumor
growth. Tumor-induced angiogenesis and tumor cell vessel interactions are one of the most
important events during all the stages of tumor development. However, it is not fully un‐
derstood what is exactly happening before or during the initiation of vascularization of the
primary tumor and the micrometastasis. In the beginning malignant cells may associate
with and grow preferentially along pre-existing microvessels, prior to building their own
vasculature. This process is called vessel co-option and was first proposed by Holash et al.
[106]. Although at first, it is limited to the early stages of human tumorigenesis, morphologi‐
cal evidence suggests that co-option of pre-existing blood vessels might persist during the
entire period of primary or metastatic tumor growth. During solid tumor growth, no signs
of directed vessel ingrowth can be appreciated; instead, these tumors decide to develop by
co-opting the massive vascular plexus present in the peritumoral connective tissue. Several
controversies have been raised regarding how tumors progress, whether microtumors may
initiate growth by exploiting pre-existing vessels without inducing angiogenesis or initiating
through the induction of angiogenic sprouts from host vessels [107]. These discrepancies
may have aroused given the differences in vascular niches in applied experimental models.
Although unresolved from a mechanistic point of view, this uncertainty may raise impor‐
tant challenges when outlining a rationale for therapeutic strategies. This implies that,
whereas compounds may be efficient inhibitors of angiogenesis and tumor growth in angio‐
genesis-dependent tumors (such as subcutaneous tumor xenografts), their effects may be
limited in tumors growing in tissues with an intrinsic vascular density that allows for co-
option by infiltrative tumors or other forms of neo-vasculature.
Based on this knowledge, new ways to inhibit the various vascular modalities have been de‐
veloped in the past decade. When applying these targeted therapies, there are several as‐
pects to take into consideration: the stage of tumor progression, the type of vascularization
of the cancerous tissue and the molecular signaling networks behind the vascularization
process.
What are the key aspects in determining the vascularization patterns of tumors? First, the
local microenvironment, important during tumor initiation. Second, the cell number, subsi‐
dizing microtumors ability of inducing angiogenesis. Moreover, to trigger exponential
growth, tumors must depend on vascularization through angiogenesis, which is much more
powerful than vessel co-option to increase the tumoral mass and to acquire nutrition and
oxygen from the host circulation system. If possible, tumors will prefer this kind of vascula‐
rization pattern. Alternatively, another choice is the strategy of co-opting host vessels in or‐
der for tumor cells to survive when they cannot acquire enough support from its niche and
have no capacity to establish intrinsic vessels through angiogenesis. This is consistent with
the observations that anti-angiogenic therapies result in an increase of vascular co-option
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[108]. Third, the co-option and migration along host vessels will be inhibited once angiogen‐
ic sprouts begin to be induced.
Of note in liver metastases of human colorectal carcinomas, different growth patterns can be
observed, depending on the degree of differentiation. These liver metastases represent a tru‐
ly heterogeneous group and their growth patterns (replacement, pushing and desmoplastic)
predict the fraction of immature blood vessels, the fraction of proliferating endothelial cells
and the fraction of apoptotic tumor cells. The replacement growth pattern expands mainly
by co-opting the stroma with the sinusoidal blood vessels of the liver [109].
The use of anti-vascular endothelial growth factor antibodies have been used for the abroga‐
tion of angiogenesis and growth of human prostate carcinoma microtumors and even meta‐
stasis in orthotopic prostate cancer xenografts. Although up to date there are no reports
suggesting that vessel co-option is also an alternative route for growth and dissemination of
prostate tumors, the contribution of this vascular route to prostate tumorigenesis needs fur‐
ther exploration; specifically, the involvement of this survival tool for growth of microtu‐
mors [110, 111].
Many studies have reported the close association between host vessels and extravasated
cells during the onset of metastases. The co-opting manner makes these tumoral cells cover
vessel surface area as much as possible and obtain the necessary support from host, such as
nutrients or oxygen, with remarkable vessel-like pseudopodia. As Weinberg articulated for
this kind of behaviour “tumor cells require effective interactions with the vasculature in or‐
der to acquire nutrients and to shed metabolic waste products and carbon dioxide.... In some
normal tissues with an especially high metabolic activity, most cells enjoy direct contact
with at least one capillary. This intimate association means that their access to oxygen and
critical nutrients not dependent on the diffusion of these molecules over large distances and
through densely packed cell layers” [112].
The tumoral vascular picture clearly displays differential contributions of vessel co-option
and angiogenesis at the earliest stage of tumor initiation and metastasis. While angiogenesis
appears as a key player for tumor exponential growth, the strategy of co-opting host vessels
seems indispensable for cancer cell survival. Future anti-vascular therapies should seriously
take into consideration the alternative ways in which a tumor disseminate and evades con‐
ventional anti-angiogenic treatments.
2.4.3. Vasculogenic mimicry
How can we distinguish normal angiogenesis from tumor-associated angiogenesis? Tumor
neovasculature is marked by precocious capillary sprouting, convoluted and excessive ves‐
sel branching, distorted and enlarged vessels, erratic blood flow, leakiness leading to blood
lakes, and distorted levels of endothelial cell proliferation and apoptosis [59]. Also, certain
types of cancer cells have the capacity to mimic the activities of endothelial cells and to par‐
ticipate in processes that involve the formation of a fluid-conducting, matrix-rich meshwork,
metamorphosing into vessels that either carry blood or connect to the host’s blood supply.
This new mechanism, by which some aggressive tumors may acquire a blood supply, was
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first described by Maniotis and coworkers [113] and was termed ‘vasculogenic mimicry’.
However, it cannot be considered a vasculogenic event as true vasculogenesis involves de
novo formation of endothelial cell-lined vessels. Since its discovery, vasculogenic mimicry
has been catalogued in several types of tumors. How does vasculogenic mimicry contribute
to tumor growth and progression, and can it be targeted by therapeutic agents?
Several interpretations of vasculogenic mimicry have evolved since tumor angiogenesis was
recognized as not the only mechanism of blood supply for tumor microcirculation. Vasculo‐
genic mimicry describes the ability of aggressive tumoral cells to express endothelium-asso‐
ciated genes and to form ECM-rich vasculogenic-like networks in three-dimensional (3D)
cultures. These new vessels have no endothelial lining and are mainly composed of base‐
ment membrane-like material. The formation of these networks, seem to mimic the embry‐
onic development of vasculogenic meshes and they were associated with the distinctly
patterned ECM-rich networks that are observed in aggressive tumors. Since its discovery,
vasculogenic mimicry has been described in several kinds of tumors, including melanoma,
synovial sarcoma, rhabdomyosarcoma, osteosarcoma, breast carcinoma and ovarian carcino‐
ma. Most of these studies correlate the aggressiveness of the tumor with angiogenesis or
vasculogenic mimicry proliferation [114]. But how do they form and what is their contribu‐
tion to tumorigenesis?
In the beginning, researchers observed in xenograft models and human biopsies, patterned
loops and arcs that confined spheroidal clusters of tumoral cells. These loops and arcs
formed networks that were lined with cancer cells and contained laminin and other compo‐
nents of the ECM yet not explored. Studies of tumor-tissue sections showed that the spheroi‐
dal tumor clusters contained either small, channel-like spaces between them, or seemed to
be partially or totally juxtaposed by ECM. Some of these channel-like spaces were originally
defined as ‘vascular channels’, because they were found to contain erythrocytes and plasma
and were thought to provide a perfusion mechanism and a dissemination path within the
tumor that might work independently or together with angiogenesis or vessel co-option.
Blood lakes within the tumor are another physiological phenomena that also draw attention.
These are large collections of extravascular erythrocytes lining tumor spaces or channels. As
hemorrhage is a manifestation of the defective endothelial barrier function in tumors the
reason as why some tumors are bloodier than others, might rely on the balance between er‐
ythrocyte extravasation and the vessel wall stability. Rapid endothelial cell proliferation and
defective pericyte coverage might contribute to the instability of tumor vessel walls leading
to this hemorrhage. Pericytes are supporting cells that are closely apposed to the outer sur‐
faces of the endothelial tubes in normal tissue vasculature, providing mechanical and phys‐
iologic support to the endothelial cells and have been associated with the maintenance of a
functional neo-vasculature of most if not all tumors [115].
The literature on vasculogenic mimicry in prostate cancer is scarce, although therapeutic im‐
plications of it have been described in aggressive prostate cancer in vitro [116]. The prognos‐
tic value of vasculogenic mimicry remains debatable as there is at least one study showing
that there is no significant correlation between vasculogenic mimicry channels and histolog‐
ical grading of prostate cancer [117].
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Interestingly, Liu et al. [114] looked at this correlation in human tissue samples to determine
clinical pathology, prognosis and a possible molecular mechanism. They statistically corre‐
lated histological with clinicopathological data from prostate carcinoma cases confirming
that vasculogenic mimicry was more often seen in those patients with seminal vesicle inva‐
sion, lymph node metastasis, distant metastasis tissues or shorter PSA doubling time
(PSADT), all important clinical prognostic factors of prostate cancer. They concluded that
vasculogenic mimicry mainly exists in the high-risk prostate cancer patients and is a new
independent marker of poor prognosis of the disease. Though more studies with larger sam‐
ple sizes are needed to further confirm the correlation of vasculogenic mimicry and prostate
cancer prognosis, these results might explain why some anti-angiogenesis treatments re‐
main clinically less effective.
2.4.4. Molecular signaling
The identification of molecules that are uniquely expressed on the surface of endothelial
cells  of  tumor  vessels  has  been  a  holy  grail  of  vascular  biology.  Such  molecules  could
serve  as  therapeutical  targets.  Although there  is  no  molecule  truly  associated  to  tumor
vessels, several show higher expression in tumors. Among those relevant in prostate can‐
cer  we  find:  endoglin  (CD105),  VEGF/VEGFR-2  complexes,  thrombospondin-1  receptor
(CD36),  Thy-1  cell  surface  antigen  (Thy-1),  phosphatidylserine,  prostate-specific  mem‐
brane antigen (PSMA), MMP, Her2/Neu and multiple tumor endothelial markers. The ab‐
sence  of  absolute  specificity  of  these  molecules  for  tumor  vessels  drives  the  search  for
better targets [118]. Of note, Her2/Neu plays an important role in the spreading of pros‐
tate carcinomas to the bone and its high expression is associated with a poorer prognosis
in patients with bone metastases. The Her2/Neu receptor is part of a molecular signaling
cascade that involves Akt and MMP-9 activation, enabling the cancer cell to penetrate the
matrix and facilitating angiogenesis.
It is wise to recognize the lead role of MMP in facilitating the invasiveness of prostate can‐
cer. These molecules are important in the degradation of the ECM, allowing tumoral cells to
metastasize to distant sites throughout the body. This protease activity, not only allows for
cell migration, but also facilitate angiogenesis, providing the tumor with nutrition and fur‐
ther proliferation [119]. Of note, MMP-2 plays an important role in the preliminary stages of
the vasculogenic mimicry genesis, degrading collagen IV. Reports showed that human pros‐
tate carcinoma samples positive for vasculogenic mimicry had a significantly higher MMP-2
expression levels compared to vasculogenic mimicry-negative patients. Metastat, an inhibi‐
tor of MMP, decreased the formation of vasculogenic mimicry networks in aggressive pros‐
tate tumors. However, further studies are needed to elucidate the mechanism of formation
of vasculogenic mimicry in detail [114].
In bone metastases, the prostate metastatic tissue might allow for angiogenesis via the
MMP9 derived from osteoclasts. Interesting, some MMP have a higher expression with
higher Gleason's scores. This fact has led to the revamping of the MMP as possible prognos‐
tic factors and even more, as valid candidates for therapy. However, the MMP field is at a
crossroad; in the last few years, accumulating evidence from experimental models of cancer,
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knockout mice and proteomics studies has challenged our views on how MMP function in
the tumoral process. This challenge has been compounded by the fact that the clinical trials
with MMP inhibitors failed to show therapeutic efficacy in cancer patients. MMPs have a
vast repertoire of substrates not limited to the ECM components, and multiple proteins can
be potentially targeted by MMPs and may be important for the anti-tumor activity of the
host. This may partly explain why broad-spectrum synthetic MMP inhibitors failed to show
clinical efficacy.
The MMP picture is not simple and reveals a complex contribution to cancer progression,
putting aside the long-held view of MMP as a family that promotes cancer metastasis. To‐
day, the evidence shows that members of the MMP family may promote or inhibit cancer
development. Moreover, an individual MMP may act positively or negatively on tumor pro‐
gression depending on other factors, on the tumor stage, tumor site (primary, metastasis),
enzyme localization (tumor vs. stromal) and substrate profile [120]. In the –omics era, the
identification of the substrates targeted by MMP in biological samples, known as degrado‐
mics, promises to become an important tool for defining the role of MMP in cancer. Estab‐
lishing correlations, particularly in advanced prostate carcinomas, may assist in better
patient stratification.
2.4.5. Cell plasticity and cancer stem cells
In fact, more questions than answers have been raised about the relevance of the in vivo
studies on tumor vasculature. Is there a morphological and functional connection between
prostate  tumor-cell-lined networks  and endothelium-lined vasculature?  Is  it  possible  for
aggressive prostate cancer cells  to form functional  vessels when placed in an ischaemic,
non-tumor  microenvironment?  What  is  the  potential  relevance  of  a  ‘plastic’  tumor-cell
phenotype, and how can we identify and target tumor cells that can masquerade as other
cell types? Many of the biological properties that are relevant to embryogenesis are also
important for tumor growth. For example, during embryonic development, the formation
of primary vascular networks occurs by the process of vasculogenesis (the differentiation
of mesodermal progenitor cells (angioblasts and hemangioblasts) to endothelial cells) and
their organization into a primitive network [121]. The remodeling of the vasculogenic net‐
work into a more refined microvasculature occurs through angiogenesis in the same way
as tumors require a blood supply for growth and also use the blood supply for metastatic
dissemination [122].
Cells capable of vasculogenic mimicry display a high degree of plasticity, causing them to
resemble dedifferentiated cell types. A stem cell is considered the most dedifferentiated cell,
holding the capacity to generate various novel cell types. However, a new concept comes
into the picture, the cancer stem cells (CSCs). These cells hold the capacity to self-renew, dif‐
ferentiate and proliferate indefinitely, being the latter a key event in tumor growth. Tumoral
vasculogenic mimicry is characterized by an undifferentiated molecular signature together
with embryonic-like differentiation plasticity implying a link between cancer stem cells and
aggressive tumor cells capable of vasculogenic mimicry. Moreover, these two cell types
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share the potentiality of unlimited proliferation capacity, cellular plasticity and the expres‐
sion of a gene signature responsible of maintaining pluripotency.
Among the signaling molecules known to influence stem cell renewal and differentiation in
aggressive forms of prostate cancer, we find: Wnt, Src, BMP (bone morphogenic proteins)
and TGFβ [5]. Other transcription factors are also involved in bone metastasis. HIF1α in tu‐
mor cells, inhibits osteoblasts differentiation, induces osteoclasts differentiation and pro‐
motes tumor growth. Hypoxia and TGFβ signaling in parallel drive the development of
tumor bone metastases and regulate a common set of tumor genes stimulating the produc‐
tion of VEGF and CXCR4 in both tumor cells and bone microenvironment to enhance angio‐
genesis and tumor homing. VEGF, a target gene of Runx2, facilitates tumor growth and both
the osteolytic and the osteoblastic disease [123, 124]. Additionally, prostate cancer cell lines
express mediators of tumor growth and bone destruction, among them IL8, IL6 and PTHrP.
Runx2 is also a key regulator of metastasis related genes and its presence in the primary tu‐
mor could be critical for the diagnosis of prostate cancer bone metastasis [125].
The Notch signaling pathway is now recognized as an important player in tumor angiogen‐
esis. Two key Notch ligands have been implicated in this process, Delta-like 4 (Dll4) and Jag‐
ged1. Notch appears to be very attractive because specifically, bone metastases from
prostate cancer patients expressed Notch-1 protein in the osteoblastic lesions. Correspond‐
ingly, Notch ligand Jagged-1 was found to be highly-expressed in metastatic prostate cancer
compared to localized disease or benign prostate tissues, and high Jagged-1 expression in a
subset of clinically localized tumors was found to be significantly associated with tumor re‐
currence [5]. Although the molecular mechanism of Notch signaling is not completely un‐
derstood, silencing of Notch-1 inhibits MMP9, uPA and VEGF expression, given support to
the effect of Notch in invasion [126, 127]. Moreover, Wang et al [126] recently proposed a
down-regulated signaling cascade downstream of Notch-1, with reduced Akt and mTOR
phosphorylation and inactivated NF-κB signaling. The interplay between these pathways
provides a balance between self-renewal and differentiation. Dll4 expression activates Notch
resulting in restriction of new sprout development. In agreement with this activity, inhibi‐
tion of Dll4-mediated Notch signaling in tumors results in hyper sprouting of nonfunctional
vasculature [128]. This Dll4 inhibition may paradoxically lead to increased angiogenesis but
poor tumor growth because the newly growing vessels are not functional. In contrast, Jag‐
ged1 has been described as a Notch ligand expressed in tumor cells that may influence tu‐
mor angiogenesis by activating Notch on tumor endothelium. Of note, Notch activation is
also critical for the maintenance of stem cell self-renewal potency in several stem cell micro‐
environments. These results indicate that Notch signaling can have diverse signaling out‐
comes dependent on the cellular niche, as it is able to induce (endothelial) differentiation in
some cases, while promoting self-renewal potency in others [128].
TGFβ signaling also draws our attention given that it is a key molecule in the maintenance
of an undifferentiated state in human embryonic stem cells. Various components of the
TGFβ signaling cascade are highly expressed in stem cells, including Nodal and its regula‐
tors Cripto and LEFTY1/2 [101,102]. However little is known about signaling cascades gov‐
erning the pluripotent state [129]. Taken together multiple stimuli provided by prostate
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tumors and their effective microenvironment can trigger differential signaling cascades that
in turn will define the fate of the host. Thus a variety of therapeutic venues may have to co‐
exist in order to be translated into clinical utility.
2.4.6. Clinical significance
Undoubtfully, there are more questions than answers at this time regarding the functional
significance of vasculogenic networks and vascular marker expression by prostate cancer
cells. If tumor vasculogenesis can be demonstrated in experimental models, does it occur
concomitantly with angiogenesis or as a remodeling of angiogenesis in aggressive tumors?
Is vessel co-option involved? Is tumor cell vasculogenesis an alternative angiogenic switch
in aggressive tumors? Regardless of the terms employed to describe the expression and
mimicry of vascular-like gene by aggressive prostate cancer tumor cells, this area of research
is worthy of analysis. It is wise to consider that in addition to the current anti-vascular treat‐
ments, the novel therapeutic approaches against tumor vasculature must be harmonized
with the stage of tumor progression and with the molecular mechanism responsible for the
angiogenic phenotype.
In our perspective the challenge relies in combining the anti-vascular strategies with the ex‐
isting therapeutic regimes. The rational application of antivascular agents must be tagged
along with the notion that these therapies must be individually tailored for the different
types of cancer cells. The clinical management of prostate cancer would benefit greatly from
the better understanding of the diverse vascularization mechanisms helping to fine-tune
these novel anti-cancer strategies.
3. Conclusions
It is clear that multiple host and environmental factors contribute to prostate cancer and that
inflammation sets the scene for the appearance of a reactive stroma, providing growth fac‐
tors, chemokines and proteins that stimulate among other things, invasion. In return, this
cancer finds a fertile soil to proliferate and disseminate in the bone, which acts as a special‐
ized niche for prostate cancer cells. Moreover, the vascular compartment contributes signifi‐
cantly to prostate cancer growth through provision of oxygen and nutrients. Prostate cancer
cells break into the scene co-opting blood vessels, by intussusception or even enhancing an‐
giogenesis, attracting endothelial cells, promoting their growth in the tumor microenviron‐
ment and even transdifferentiating through the EMT. The intricacy relies on deciphering the
diabolic liaison of all these factors and physiological processes. How can successful thera‐
peutic strategies be designed if there are still so many hidden molecular variables waiting to
be unveiled? The path in building promising clinical action plans will depend on unraveling
the rheostat molecules that control the metabolic reprogramming of tumoral cells and the
tumor microenvironment. Who are the key players controlling all the biochemical reactions
producing ROS and RNS within cancer cells? Even more who are their exact targets? Several
microRNA signatures are identified and described in the inflammatory milieu associated to
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prostate cancer, hence are miRNA-base therapeutic strategies a promising option for the dis‐
ease? The possibility to target cancer cell malignancy by intervention on both its metabolic
reprogramming and its interplay with environmental factors is in truth captivating. The key
molecules and pathophysiological process outlined throughout this chapter drive home the
concept that the tumor microenvironment enhanced by an inflammatory wand offers inter‐
esting homoestatic targets for prostate cancer therapy. In this synopsis, blocking the sus‐
tained inflammatory network will offer new promising avenues to achieve significant
therapeutic gains in the treatment of prostate cancer.
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